Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency
Indexed incrossrefpubmed
Abstract
PURPOSE: Recurrent glioblastoma multiforme (GBM) is incurable with current therapies. Biallelic mismatch repair deficiency (bMMRD) is a highly penetrant childhood cancer syndrome often resulting in GBM characterized by a high mutational burden. Evidence suggests that high mutation and neoantigen loads are associated with response to immune checkpoint inhibition. PATIENTS AND METHODS: We performed exome sequencing and neoantigen prediction on 37 bMMRD cancers and compared them with childhood and adult brain neoplasms. Neoantigen prediction bMMRD GBM was compared with responsive adult cancers from multiple tissues. Two siblings with recurrent multifocal bMMRD GBM were treated with the immune checkpoint inhibitor…
Citation impact
862
total citations
- FWCI
- 79.37
- Percentile
- 100%
- References
- 27
Citations per year
Authors
42Topics & keywords
Topics
Keywords
- Medicine
- Nivolumab
- Immune checkpoint
- Cancer research
- Microsatellite instability
- Germline mutation
- Exome sequencing
- DNA mismatch repair
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.